This study will evaluate the safety and tolerability of repeated subcutaneous injections of CAD106 in patients with Alzheimer's disease.

Inclusion Criteria:

• Patients who have completed the Core study with no significant safety concerns

Exclusion Criteria:

• Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression).
• Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease.
• diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation.